Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to manufacture the active pharmaceutical ingredients (APIs) for ainuovirine.
The APIs correspond to ainuovirine tablets, which are a Category 1 oral therapy for HIV-1, and a fixed-dose combination tablet containing ainuovirine, lamivudine, and tenofovir disoproxil. Both of these drug formulations were newly included in the National Reimbursement Drug List (NRDL) in December 2023, with one of the drugs being a renewal of its previous listing.- Flcube.com
